Reddy’s issues mostly repeats

Five of the eight ‘Form 483’ observations that Dr Reddy’s recently received from the US Food and Drug Administration (FDA) following an audit at the Indian firm’s local oncology formulations plant in Duvvada were repeat issues, according to the Form 483 report that has just been released by the agency.